Sequoia Capital is one of the world’s most influential venture firms, investing from seed through growth across technology and healthcare. It combines enormous brand power, large fund capacity, and long-term company-building support. While not a dedicated neurotech firm, it has shown willingness to back major frontier neurotechnology companies at scale.

Its leadership of Neuralink’s large late-stage round is a strong signal of its appetite for neurotechnology once technical and clinical milestones are sufficiently compelling. Sequoia is not typically the first specialist neuro investor at the earliest stage, but it can become highly relevant once a company begins to look like a category-defining platform. Its role is especially important in growth rounds where scale, credibility, and long-term support matter.

Sequoia now focuses on the United States and Europe following its restructuring. For neurotech founders, it is most relevant for breakout companies with exceptional scale potential, especially in BCI and other frontier platforms. It is a defining growth-stage capital source rather than an early narrow specialist.